Skip to main content
Log in

Serum uric acid is inversely proportional to estimated stroke volume and cardiac output in a large sample of pharmacologically untreated subjects: data from the Brisighella Heart Study

  • IM - ORIGINAL
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

An IM - Commentary to this article was published on 28 May 2014

Abstract

Serum uric acid is representative for xanthine-oxidase, the key enzyme involved in the production of uric acid, which is up-regulated in the failing heart, and may play an important role in the pathophysiologic process that leads to heart failure. In our study, we investigated the relation between stroke volume, cardiac output and serum uric acid in a large sample of overall healthy pharmacologically untreated subjects. The Brisighella Heart Study included 2,939 men and women between the ages of 14–84 without prior coronary heart disease or cerebrovascular disease who were not taking antihypertensive therapy at baseline. For this study, we selected 734 adult subjects enrolled in the last Brisighella population survey not taking antihypertensive, antidiabetic, lipid-lowering and uric acid-lowering drugs, and who were also not affected by chronic heart failure or by gout. The main predictors of cardiac functionality parameters were mean arterial pressure (MAP), HR, SUA and age (all p < 0.001), while gender, BMI, LDL-cholesterol, HDL-cholesterol, triglycerides, fasting plasma glucose, creatinine, estimated glomerular filtration rate, physical activity and smoking habit were not significantly associated (all p > 0.05). In particular, there is a strong relation between estimated cardiac output and serum uric acid (B = −0.219, p < 0.001) and between stroke volume and serum uric acid (B = −3.684, p < 0.001). These observations might have an impact on future considerations about serum uric acid as an early inexpensive marker of heart function decline in the general population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Pasalic D, Marinkovic N, Feher-Turkovic L (2012) Uric acid as one of the important factors in multifactorial disorders–facts and controversies. Biochem Med 22:63–75

    Article  CAS  Google Scholar 

  2. Soltani Z, Rasheed K, Kapusta DR, Reisin E (2013) Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal? Curr Hypertens Rep 15(3):175–181. doi:10.1007/s11906-013-0344-5

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Kivity S, Kopel E, Maor E, Abu-Bachar F, Segev S, Sidi Y, Olchovsky D (2013) Association of serum uric acid and cardiovascular disease in healthy adults. Am J Cardiol 111:1146–1151. doi:10.1016/j.amjcard.2012.12.034

    Article  CAS  PubMed  Google Scholar 

  4. Duan X, Ling F (2008) Is uric acid itself a player or a bystander in the pathophysiology of chronic heart failure? Med Hypotheses 70:578–581

    Article  CAS  PubMed  Google Scholar 

  5. Shankar A, Klein R, Klein BEK, Nieto FJ (2006) The association between serum UA level and long-term incidence of hypertension: population based cohort study. J Hum Hypertens 20:937–945

    Article  CAS  PubMed  Google Scholar 

  6. Taniguchi Y, Hayashi T, Tsumura K, Endo G, Fujii S, Okada K (2001) Serum UA and the risk for hypertension and type 2 diabetes in Japanese men: the Osaka Health Survey. J Hypertens 19:1209–1215

    Article  CAS  PubMed  Google Scholar 

  7. Harzand A, Tamariz L, Hare JM (2012) Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition. Congest Heart Fail 18:179–182. doi:10.1111/j.1751-7133.2011.00262.x

    Article  CAS  PubMed  Google Scholar 

  8. Tamariz L, Harzand A, Palacio A, Verma S, Jones J, Hare J (2011) UA as a predictor of all-cause mortality in HF: a meta-analysis. Congest Heart Fail 17:25–30. doi:10.1111/j.1751-7133.2011.00200.x

    Article  PubMed  Google Scholar 

  9. Cicero AFG, Dormi A, D’Addato S, Borghi C (2011) From risk factor assessment to cardiovascular disease risk and mortality modification. The first 40 years of the Brisighella Heart Study. Clin Lipidol 6:269–276

    Article  Google Scholar 

  10. Cicero AFG, D’Addato S, Santi F, Ferroni A, Borghi C, on behalf of the Brisighella Heart Study group (2012) Leisure-time physical activity and cardiovascular disease mortality: the Brisighella Heart Study. J Cardiovasc Med 13:559–564

    Article  Google Scholar 

  11. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International diabetes federation task force on epidemiology and prevention; National heart, lung, and blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645

    Article  CAS  PubMed  Google Scholar 

  12. Hickson SS, Butlin M, Broad J, Avolio AP, Wilkinson IB, McEniery CM (2009) Validity and repeatability of the Vicorder apparatus: a comparison with the SphygmoCor device. Hypertens Res 32:1079–1085. doi:10.1038/hr.2009

    Article  PubMed  Google Scholar 

  13. Pucci G, Cheriyan J, Hubsch A, Hickson SS, Gajendragadkar PR, Watson T, O’Sullivan M, Woodcock-Smith J, Schillaci G, Wilkinson IB, McEniery CM (2013) Evaluation of the Vicorder, a novel cuff-based device for the noninvasive estimation of central blood pressure. J Hypertens 31:77–85. doi:10.1097/HJH.0b013e32835a8eb1

    Article  CAS  PubMed  Google Scholar 

  14. Jessup M, Brozena S (2003) Heart failure. N Engl J Med 348:2007–2018

    Article  PubMed  Google Scholar 

  15. Floras JS (2009) Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol 54:375–385. doi:10.1016/j.jacc.2009.03.061

    Article  CAS  PubMed  Google Scholar 

  16. Zimmet JM, Hare JM (2006) Nitroso-redox interactions in the cardiovascular system. Circulation 114:1531–1544

    Article  PubMed  Google Scholar 

  17. Mann DL (2002) Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91:988–998

    Article  CAS  PubMed  Google Scholar 

  18. Jeemon P, Prabhakaran D (2013) Does uric acid qualify as an independent risk factor for cardiovascular mortality? Clin Sci (Lond) 124:255–257. doi:10.1042/CS20120524

    Article  CAS  Google Scholar 

  19. Amin A, Vakilian F, Maleki M (2011) Serum uric acid levels correlate with filling pressures in systolic heart failure. Congest Heart Fail 17:80–84. doi:10.1111/j.1751-7133.2010.00205.x

    PubMed  Google Scholar 

  20. Krishnan E, Hariri A, Dabbous O, Pandya BJ (2012) Hyperuricemia and the echocardiographic measures of myocardial dysfunction. Congest Heart Fail 18:138–143. doi:10.1111/j.1751-7133.2011.00259.x

    Article  CAS  PubMed  Google Scholar 

  21. Krishnan E (2009) Hyperuricemia and incident heart failure. Circ Heart Fail 2:556–562. doi:10.1161/CIRCHEARTFAILURE.108.797662

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Baldasseroni S, Urso R, Maggioni AP, Orso F, Fabbri G, Marchionni N, Tavazzi L, IN-CHF Investigators (2012) Prognostic significance of serum uric acid in outpatients with chronic heart failure is complex and related to body mass index: data from the IN-CHF Registry. Nutr Metab Cardiovasc Dis 22:442–448. doi:10.1016/j.numecd.2010.08.007

    Article  CAS  PubMed  Google Scholar 

  23. Tang ZH, Fang Z, Zeng F, Li Z, Zhou L (2013) Association and interaction analysis of metabolic syndrome and serum uric acid on diastolic heart failure. J Endocrinol Invest [Epub ahead of print]

  24. Mulè G, Nardi E, Costanzo M, Mogavero M, Guarino L, Viola T, Vario MG, Cacciatore V, Andronico G, Cerasola G, Cottone S (2013) Absence of an independent association between serum uric acid and left ventricular mass in Caucasian hypertensive women and men. Nutr Metab Cardiovasc Dis 23:715–722. doi:10.1016/j.numecd.2012.01.007

    Article  PubMed  Google Scholar 

  25. Savarese G, Ferri C, Trimarco B, Rosano G, Dellegrottaglie S, Losco T, Casaretti L, D’Amore C, Gambardella F, Prastaro M, Rengo G, Leosco D, Perrone-Filardi P (2013) Changes in serum uric acid levels and cardiovascular events: a meta-analysis. Nutr Metab Cardiovasc Dis 23:707–714. doi:10.1016/j.numecd.2013.03.001

    Article  CAS  PubMed  Google Scholar 

  26. Springer J, Tschirner A, Hartman K, von Haehling S, Anker SD, Doehner W (2013) The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy. Int J Cardiol. doi:10.1016/j.ijcard.2013.05.063

    Google Scholar 

  27. Baldus S, Müllerleile K, Chumley P, Steven D, Rudolph V, Lund GK, Staude HJ, Stork A, Köster R, Kähler J, Weiss C, Münzel T, Meinertz T, Freeman BA, Heitzer T (2006) Inhibition of xanthine oxidase improves myocardial contractility in patients with ischemic cardiomyopathy. Free Radic Biol Med 41:1282–1288

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Arrigo Francesco Giuseppe Cicero.

Additional information

For the Brisighella Heart Study group.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cicero, A.F.G., Rosticci, M., Parini, A. et al. Serum uric acid is inversely proportional to estimated stroke volume and cardiac output in a large sample of pharmacologically untreated subjects: data from the Brisighella Heart Study. Intern Emerg Med 9, 655–660 (2014). https://doi.org/10.1007/s11739-013-1016-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-013-1016-9

Keywords

Navigation